为睾丸癌选择合适的人绒毛膜促性腺激素检测方法迈进一步
生殖细胞肿瘤管理指南推荐检测hCG和/或游离hCGβ用于早期诊断、预后评估和化疗后监测,但市售hCG检测仅获批用于妊娠。Elecsys「hCG+β」是欧洲唯一获批肿瘤应用的检测。该文讨论肿瘤用途hCG检测的分析要求,并基于3年临床经验提出按性别和年龄分层的决策限。
要点
- 肿瘤用途hCG检测应等摩尔识别完整hCG和hCGβ单体。
- Elecsys检测限0.2 U/L、LH交叉反应0.12%,可能满足推荐要求。
- 基于3年经验提出按性别和年龄分层的肿瘤决策限。
核心结论
- 肿瘤用途hCG检测需满足等摩尔识别完整hCG和hCGβ单体的抗体要求,并兼顾分析敏感性和低LH交叉反应。
- Elecsys「hCG+β」是欧洲唯一获批肿瘤应用的hCG检测,其检测限和LH交叉反应可能满足推荐要求。
- 基于3年临床经验,可定义按性别和年龄分层的肿瘤决策限。
研究设计与样本
- 本文为针对hCG检测在睾丸癌中应用的论述性文章,包含对国际肿瘤与生物标志物学会推荐的分析要求的讨论,以及使用Elecsys检测3年的临床经验总结。
主要发现
- 市售hCG检测除Elecsys「hCG+β」外均仅获批用于妊娠。
- Elecsys检测的检测限为0.2 U/L,对LH的交叉反应为0.12%。
- 基于3年肿瘤临床经验定义的决策限为:男性<50岁0.3 U/L;男性>50岁2.3 U/L;女性<50岁2.1 U/L;女性>50岁5.6 U/L。
关键数值与推荐
- 国际肿瘤与生物标志物学会推荐肿瘤用途hCG检测使用等摩尔识别完整hCG和hCGβ单体的抗体。
- 肿瘤用途hCG检测还应考虑最佳分析敏感性以允许早期肿瘤检测,以及低LH交叉反应。
- Elecsys检测限0.2 U/L和LH交叉反应0.12%与推荐要求相比可能足够。
- 肿瘤决策限按性别和年龄分层:男性<50岁0.3 U/L;男性>50岁2.3 U/L;女性<50岁2.1 U/L;女性>50岁5.6 U/L。
临床怎么用
- 临床应使用专门为癌症应用制造的选择性高、敏感且精密的hCG检测,如Elecsys「hCG+β」。
- 解读hCG结果时应参考按性别和年龄分层的肿瘤决策限。
- 需传播适当的教育信息以促进肿瘤用途hCG检测的临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical practice guidelines for the management of germ cell tumors recommend the measurements of human chorionic gonadotropin (hCG) and/or free hCGβ subunit for earlier diagnosis/recognition of the residual disease, for the prognostic evaluation and for the post-chemotherapy surveillance. However, the marketed hCG assays are validated and approved only for pregnancy purposes, with the sole exception of the Elecsys 'hCG+β' assay (Roche Diagnostics), cleared in Europe for oncological application. Theoretically, the hCG assay design for oncological purposes should fulfil the recommendations of the International Society of Oncology and Biomarkers requiring the use of antibodies displaying an equimolar recognition of both intact hCG and hCGβ monomer. Further analytical requirements should also be considered, such as optimal analytical sensitivity to allow an early tumor detection and low cross-reactivity for luteinizing hormone (LH). For the Elecsys assay, the detection limit (0.2 U/L) and the reported cross-reactivity for LH (0.12%) may be considered adequate if compared with the recommended requirements. Another issue is the definition of decision limits for oncologic purposes. After 3 years of clinical experience using the Elecsys assay in the oncology setting, we were able to define limits partitioned by sex and age as follows: males <50 years, 0.3 U/L; males >50 years, 2.3 U/L; female <50 years, 2.1 U/L; female >50 years, 5.6 U/L. There is an urgent need to disseminate appropriate educational information and to boost the clinical use of selective, highly sensitive and precise assays, specifically manufactured for cancer application.
引用
- Ferraro S, Panteghini M. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer. Clin Chem Lab Med. 2020. PMID: 31199761. doi:10.1515/cclm-2019-0319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。